



Aldeyra Therapeutics to Participate in Upcoming Virtual Investor Conferences

March 2, 2021

LEXINGTON, Mass.--(BUSINESS WIRE)--Mar. 2, 2021-- [Aldeyra Therapeutics, Inc.](#) (Nasdaq: ALDX) (Aldeyra) today announced that President and Chief Executive Officer Todd C. Brady, M.D., Ph.D. will participate in analyst-led fireside conversations at the H.C. Wainwright Global Life Sciences Conference and the Oppenheimer 31st Annual Healthcare Conference.

- **H.C. Wainwright Global Life Sciences Conference**

Date: Tuesday, March 9, 2021

Time: 7:00 a.m. ET

- **Oppenheimer 31st Annual Healthcare Conference**

Date: Tuesday, March 16, 2021

Time: 9:20 a.m. ET

To view these events, please visit the [Investor & Media page](#) of the company's website. After the presentations, the events will remain archived on the website for 90 days.

About Aldeyra Therapeutics, Inc.

Aldeyra Therapeutics is a clinical-stage biotechnology company focused on the development of novel therapies with the potential to improve the lives of patients with immune-mediated diseases. Two of the company's lead investigational compounds, reproxalap and ADX-629, target RASP (reactive aldehyde species), which are elevated in ocular and systemic inflammatory disease and result in cytokine release via activation of a broad array of inflammatory factors, including NF- κ B, inflammasomes, and Scavenger Receptor A. Reproxalap is being evaluated in Phase 3 clinical trials in patients with dry eye disease and allergic conjunctivitis. The company's clinical pipeline also includes ADX-2191, a dihydrofolate reductase inhibitor in Phase 3 testing for proliferative vitreoretinopathy, and ADX-1612, a chaperome inhibitor in development for COVID-19 and ovarian cancer. For more information, visit <https://www.aldeyra.com/> and follow us on [LinkedIn](#), [Facebook](#), and [Twitter](#).

View source version on [businesswire.com](https://www.businesswire.com/news/home/20210302005108/en/): <https://www.businesswire.com/news/home/20210302005108/en/>

Corporate Contact:

Joshua Reed

Aldeyra Therapeutics, Inc.

Tel: 781-761-4904 ext. 218

jreed@aldeyra.com

Investor & Media Contact:

Scott Solomon

Sharon Merrill Associates, Inc.

Tel: 617-542-5300

ALDX@investorrelations.com

Source: Aldeyra Therapeutics, Inc.